Research map: Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC

Back to the article

Papers in this map

  1. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics · Yoshinobu Kanda · 2012 · 19329 citations · Cited by this paper
  2. Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis · 2026 · Related
  3. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer · Leena Gandhi · 2018 · 6765 citations · Cited by this paper
  4. Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study · 2026 · Related
  5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial · Howard West · 2019 · 1712 citations · Cited by this paper
  6. The role of surgical timing in survival of patients with spinal metastases · 2026 · Related
  7. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial · Luis G Paz-Ares · 2021 · 1397 citations · Cited by this paper
  8. Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis · 2026 · Related
  9. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer · Shirish M. Gadgeel · 2020 · 1182 citations · Cited by this paper
  10. Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer · 2026 · Related
  11. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 · Julie Renee Brahmer · 2022 · 409 citations · Cited by this paper
  12. Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing · 2026 · Related
  13. Gene signature driving invasive mucinous adenocarcinoma of the lung · Minzhe Guo · 2017 · 136 citations · Cited by this paper
  14. Positive peritoneal cytology and recurrence patterns in endometrial cancer according to postoperative recurrence risk classification: a retrospective cohort study · 2026 · Related
  15. Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy · Jong‐Mu Sun · 2011 · 125 citations · Cited by this paper
  16. Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma · 2026 · Related
  17. Thyroid Transcription Factor-1 (TTF-1) Expression in Human Lung Carcinomas: Its Prognostic Implication and Relationship with Expressions of p53 and Ki-67 Proteins · Na Hye Myong · 2003 · 72 citations · Cited by this paper
  18. Prognostic significance of predicted skeletal muscle index after curative-intent resection for non-small cell lung cancer · 2026 · Related
  19. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas · Juliana B. Schilsky · 2017 · 72 citations · Cited by this paper
  20. RNF125 mediates the anti-breast cancer activity of betulinic acid through ubiquitin-dependent degradation of MYH9 · 2026 · Related
  21. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis · Nikolaj Frost · 2020 · 57 citations · Cited by this paper
  22. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial · Yoshimasa Shiraishi · 2024 · 49 citations · Cited by this paper
  23. Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinoma · Kenji Nakahama · 2022 · 29 citations · Cited by this paper
  24. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer · Ritsu Ibusuki · 2022 · 26 citations · Cited by this paper
  25. Roles of Thyroid Transcription Factor 1 in Lung Cancer Biology · Cody A. Phelps · 2017 · 25 citations · Cited by this paper
  26. Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer · Yunfen Zu · 2012 · 24 citations · Cited by this paper
  27. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy · Ondřej Fiala · 2017 · 22 citations · Cited by this paper
  28. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer · Hirokazu Iso · 2023 · 22 citations · Cited by this paper
  29. Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy · Mark K. Doherty · 2018 · 12 citations · Cited by this paper
  30. Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study · Naoya Nishioka · 2024 · 7 citations · Cited by this paper
  31. Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study · Naoya Nishioka · 2024 · 6 citations · Cited by this paper
  32. Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer · Akira Nakao · 2022 · 5 citations · Cited by this paper
  33. Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer · Mark Uhlenbruch · 2024 · 4 citations · Cited by this paper
  34. Diffuse and Strong TTF-1 Expression Predicts Response to Pemetrexed-Based Immunochemotherapy in Advanced Lung Adenocarcinoma · Jun Yamada · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)